120 related articles for article (PubMed ID: 38552378)
1. Tubuloside B, a major constituent of Cistanche deserticola, inhibits migration of hepatocellular carcinoma by inhibiting Hippo-YAP pathway.
Yao J; Wan H; Zhang J; Shen W; Wei X; Shi C; Ou B; Liu D; Ge L; Fei J; Zeng X
Phytomedicine; 2024 Jul; 129():155552. PubMed ID: 38552378
[TBL] [Abstract][Full Text] [Related]
2. Evodiamine inhibits proliferation and promotes apoptosis of hepatocellular carcinoma cells via the Hippo-Yes-Associated Protein signaling pathway.
Zhao S; Xu K; Jiang R; Li DY; Guo XX; Zhou P; Tang JF; Li LS; Zeng D; Hu L; Ran JH; Li J; Chen DL
Life Sci; 2020 Jun; 251():117424. PubMed ID: 32057900
[TBL] [Abstract][Full Text] [Related]
3. Tubuloside B, isolated from Cistanche tubulosa, a promising agent against M1 macrophage activation via synergistically targeting Mob1 and ERK1/2.
Xiao L; Yao J; Miao Y; Ou B; Wang J; Huang Y; Zhou B; Ge L; Tian J; Zeng X
Biomed Pharmacother; 2022 Sep; 153():113414. PubMed ID: 36076538
[TBL] [Abstract][Full Text] [Related]
4. Artemisinin suppresses hepatocellular carcinoma cell growth, migration and invasion by targeting cellular bioenergetics and Hippo-YAP signaling.
Li Y; Lu J; Chen Q; Han S; Shao H; Chen P; Jin Q; Yang M; Shangguan F; Fei M; Wang L; Liu Y; Liu N; Lu B
Arch Toxicol; 2019 Nov; 93(11):3367-3383. PubMed ID: 31563988
[TBL] [Abstract][Full Text] [Related]
5. c-Src promotes the growth and tumorigenesis of hepatocellular carcinoma via the Hippo signaling pathway.
Yang J; Zhang X; Liu L; Yang X; Qian Q; Du B
Life Sci; 2021 Jan; 264():118711. PubMed ID: 33186566
[TBL] [Abstract][Full Text] [Related]
6. A novel lncRNA uc.134 represses hepatocellular carcinoma progression by inhibiting CUL4A-mediated ubiquitination of LATS1.
Ni W; Zhang Y; Zhan Z; Ye F; Liang Y; Huang J; Chen K; Chen L; Ding Y
J Hematol Oncol; 2017 Apr; 10(1):91. PubMed ID: 28420424
[TBL] [Abstract][Full Text] [Related]
7. ZNF213 negatively controls triple negative breast cancer progression via Hippo/YAP signaling.
Liu Y; Su P; Zhao W; Li X; Yang X; Fan J; Yang H; Yan C; Mao L; Ding Y; Zhu J; Niu Z; Zhuang T
Cancer Sci; 2021 Jul; 112(7):2714-2727. PubMed ID: 33939216
[TBL] [Abstract][Full Text] [Related]
8. SEPT6 drives hepatocellular carcinoma cell proliferation, migration and invasion via the Hippo/YAP signaling pathway.
Fan Y; Du Z; Ding Q; Zhang J; Op Den Winkel M; Gerbes AL; Liu M; Steib CJ
Int J Oncol; 2021 Jun; 58(6):. PubMed ID: 33846777
[TBL] [Abstract][Full Text] [Related]
9. Pien Tze Huang Inhibits Migration and Invasion of Hepatocellular Carcinoma Cells by Repressing PDGFRB/YAP/CCN2 Axis Activity.
Luo ZY; Tian Q; Cheng NM; Liu WH; Yang Y; Chen W; Zhang XZ; Zheng XY; Chen MS; Zhuang QY; Zhao BX; Liu CS; Liu XL; Li Q; Wang YC
Chin J Integr Med; 2024 Feb; 30(2):115-124. PubMed ID: 35947230
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of CYR61 by TGF-β and YAP signaling exerts a counter-suppression of hepatocellular carcinoma.
Zhang C; Wei W; Tu S; Liang B; Li C; Li Y; Luo W; Wu Y; Dai X; Wang Y; Zheng L; Hao L; Zhang C; Luo Z; Chen YG; Yan X
J Biol Chem; 2024 Apr; 300(4):107208. PubMed ID: 38521502
[TBL] [Abstract][Full Text] [Related]
11. Nuclear translocation and activation of YAP by hypoxia contributes to the chemoresistance of SN38 in hepatocellular carcinoma cells.
Dai XY; Zhuang LH; Wang DD; Zhou TY; Chang LL; Gai RH; Zhu DF; Yang B; Zhu H; He QJ
Oncotarget; 2016 Feb; 7(6):6933-47. PubMed ID: 26771844
[TBL] [Abstract][Full Text] [Related]
12. Regulation of Hippo/YAP signaling and Esophageal Squamous Carcinoma progression by an E3 ubiquitin ligase PARK2.
Zhou X; Li Y; Wang W; Wang S; Hou J; Zhang A; Lv B; Gao C; Yan Z; Pang D; Lu K; Ahmad NH; Wang L; Zhu J; Zhang L; Zhuang T; Li X
Theranostics; 2020; 10(21):9443-9457. PubMed ID: 32863938
[No Abstract] [Full Text] [Related]
13. LMO3 promotes hepatocellular carcinoma invasion, metastasis and anoikis inhibition by directly interacting with LATS1 and suppressing Hippo signaling.
Cheng Y; Hou T; Ping J; Chen T; Yin B
J Exp Clin Cancer Res; 2018 Sep; 37(1):228. PubMed ID: 30219064
[TBL] [Abstract][Full Text] [Related]
14. Integrin α2β1 inhibits MST1 kinase phosphorylation and activates Yes-associated protein oncogenic signaling in hepatocellular carcinoma.
Wong KF; Liu AM; Hong W; Xu Z; Luk JM
Oncotarget; 2016 Nov; 7(47):77683-77695. PubMed ID: 27765911
[TBL] [Abstract][Full Text] [Related]
15. The RNF214-TEAD-YAP signaling axis promotes hepatocellular carcinoma progression via TEAD ubiquitylation.
Lin M; Zheng X; Yan J; Huang F; Chen Y; Ding R; Wan J; Zhang L; Wang C; Pan J; Cao X; Fu K; Lou Y; Feng XH; Ji J; Zhao B; Lan F; Shen L; He X; Qiu Y; Jin J
Nat Commun; 2024 Jun; 15(1):4995. PubMed ID: 38862474
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of Rac GTPase Activating Protein 1 Contributes to Proliferation of Cancer Cells by Reducing Hippo Signaling to Promote Cytokinesis.
Yang XM; Cao XY; He P; Li J; Feng MX; Zhang YL; Zhang XL; Wang YH; Yang Q; Zhu L; Nie HZ; Jiang SH; Tian GA; Zhang XX; Liu Q; Ji J; Zhu X; Xia Q; Zhang ZG
Gastroenterology; 2018 Oct; 155(4):1233-1249.e22. PubMed ID: 30009820
[TBL] [Abstract][Full Text] [Related]
17. TAZ target gene ITGAV regulates invasion and feeds back positively on YAP and TAZ in liver cancer cells.
Weiler SME; Lutz T; Bissinger M; Sticht C; Knaub M; Gretz N; Schirmacher P; Breuhahn K
Cancer Lett; 2020 Mar; 473():164-175. PubMed ID: 31904487
[TBL] [Abstract][Full Text] [Related]
18. LncRNA MALAT1/miR-181a-5p affects the proliferation and adhesion of myeloma cells via regulation of Hippo-YAP signaling pathway.
Sun Y; Jiang T; Jia Y; Zou J; Wang X; Gu W
Cell Cycle; 2019 Oct; 18(19):2509-2523. PubMed ID: 31397203
[TBL] [Abstract][Full Text] [Related]
19. YAP Subcellular Localization and Hippo Pathway Transcriptome Analysis in Pediatric Hepatocellular Carcinoma.
LaQuaglia MJ; Grijalva JL; Mueller KA; Perez-Atayde AR; Kim HB; Sadri-Vakili G; Vakili K
Sci Rep; 2016 Sep; 6():30238. PubMed ID: 27605415
[TBL] [Abstract][Full Text] [Related]
20. Complex roles of Hippo-YAP/TAZ signaling in hepatocellular carcinoma.
Shi H; Zou Y; Zhong W; Li Z; Wang X; Yin Y; Li D; Liu Y; Li M
J Cancer Res Clin Oncol; 2023 Nov; 149(16):15311-15322. PubMed ID: 37608027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
